SAN DIEGO, CA , June 17, 2021 – Multimeric Biotherapeutics, Inc., a biotechnology company developing vaccines against cancer and infectious diseases, announced today that it has been accepted to present at the Keystone Symposium on Innovative Vaccine Approaches. The meeting will be held as a virtual web conference scheduled June 28-30, 2021.
SAN DIEGO, CA, Sept. 15, 2020 – Multimeric Biotherapeutics, Inc. (“Multimeric” or the “Company”), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No. 10/774/149 B2, entitled “Composition Comprised of Antigen Linked to a TNF Superfamily Ligand.” Joint inventors are Geoffrey W. Stone and Richard S. Kornbluth.
Continue ReadingSAN DIEGO, CA, Dec. 25, 2019 – Multimeric Biotherapeutics, Inc. (“Multimeric” or the “Company”), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced that the European Patent Office (EPO) has issued Patent No. EP 2 970 427 B1, entitled “Composition Comprised of Antigen Linked to a TNF Superfamily Ligand.” Joint inventors are Geoffrey W. Stone and Richard S. Kornbluth.
Continue ReadingSAN DIEGO, CA , March 5, 2019 – Multimeric Biotherapeutics, Inc., a biotechnology company developing vaccines against cancer and infectious diseases, announced today that it has been accepted to present at the Immunology 2019 meeting to be held in San Diego, CA. The title of the Company’s abstract is “CD40 ligand (CD40L) multi- trimer antigen fusion protein (FortiVacTM) as a vaccine design for high-level CD8+ T cell responses.”
SAN DIEGO, CA, Sept. 11, 2018 – Multimeric Biotherapeutics, Inc. (“Multimeric” or the “Company”), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No. 10,072,064, entitled “Composition Comprised of Antigen Linked to a TNF Superfamily Ligand.” Joint inventors are Geoffrey W. Stone and Richard S. Kornbluth.
Continue Reading